Phase II clinical study of a new generation oral small molecule JAK1-selective inhibitor for multiple indications successfully initiated Recently, the clinical phase II study of LW402, a novel oral highly JAK1-selective inhibitor developed by LWBP, for the treatment of autoimmune diseases such as atopic dermatitis(AD) and rheumatoid ar... Company News Jun 5, 2023
New Class I Bifunctional Hepatitis B Drug Makes Clinical Positive progression Recently, the Bifunctional hepatitis B drug-LW 231, self-developed by Shanghai Longwood Biopharmaceuticals Co., LTD., has made positive progress in the phase I clinical study. Hepatitis B virus (HBV) ... Company News Jun 5, 2023
Longwood Biopharmaceuticals initiates clinical phase II study of LW402, a next-generation JAK1 inhibitor Longwood Biopharmaceuticals initiates clinical phase II study of LW402, a next-generation JAK1 inhibitor Recently, Longwood Biopharmaceuticals announced the initiation of a Phase II clinical study of ... Company News Mar 30, 2023
LongwoodPharmaceuticals Deeply Committed to the Pharmaceutical Industry, Contributing to the Health of China 时间：2021年08月02日 14:31 栏目：广特播报 作者：广通社 Science and technology self-reliance and self-improvement is the strategic support of national development, adhere to scientific and technological innovation is dri... Company News Mar 30, 2023